Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04338659 Completed - Clinical trials for Advanced Malignant Tumors Lymphomas

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Start date: January 14, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

NCT ID: NCT04337463 Recruiting - Clinical trials for Advanced Solid Tumor

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Start date: April 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.

NCT ID: NCT04337203 Completed - Cancer Clinical Trials

Shared Healthcare Actions and Reflections Electronic Systems in Survivorship

Start date: September 8, 2020
Phase: N/A
Study type: Interventional

The primary purpose of this study is conduct a pilot study testing the study protocols, implementation program, and mixed-methods data collection.

NCT ID: NCT04336839 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Portal Vein Resection in Pancreatic Neuroendocrine Tumours

PVNET
Start date: May 1, 2020
Phase:
Study type: Observational

The limited evidence on the value of portal vein resection in patients with borderline resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective multicentre study amongst centres with specific interest in the management of PanNENs and with experience on vascular reconstruction. Unlike previous studies on pancreatic cancer, it is more difficult to standardise the comparative parameters as the definition of borderline resectable disease has never been published for PanNENs. Similarly, different histological classifications make impossible to collect data exclusively on T3 tumours. Therefore, we aim to compare the short and long-term outcomes (including the impact of the histological depth of vascular invasion on survival) between patients undergoing standard PD and PD with portal vein resection for PanNENs, (regardless of T stage), by collecting and analysing retrospective data in this single centre study

NCT ID: NCT04336124 Completed - Advanced Cancer Clinical Trials

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Start date: May 25, 2020
Phase: Phase 1
Study type: Interventional

CVM-1118 Immediate-release (IR) Capsule and CVM-1118 Extended-release (ER) Capsule are proprietary oncology products developed by TaiRx, Inc. for the treatment of patients suffering from advanced cancer. Due to the short elimination half-life of CVM-1118 IR capsules, the extended release (ER) formulation, containing mini-tablets in hard capsule, has been developed to prolong the drug absorption and longer exposure after oral administration. The designed dose of CVM-1118 ER was 200 mg per capsule to provide a more patient-compliant and safe dosage of CVM-1118. The clinical study CVMEX-001 is therefore designed to evaluate the safety and pharmacokinetics of CVM-1118 extend release (ER) Capsule (200 mg/capsule) in patients with advanced cancer.

NCT ID: NCT04336098 Completed - Clinical trials for Advanced Solid Tumor

Study of SRF617 in Patients With Advanced Solid Tumors

Start date: March 16, 2020
Phase: Phase 1
Study type: Interventional

A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.

NCT ID: NCT04335669 Recruiting - Breast Cancer Clinical Trials

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Start date: December 20, 2019
Phase: Phase 3
Study type: Interventional

Primary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer. Pembrolizumab is allowed in both arms after approval for TNBC 2022.

NCT ID: NCT04335604 Completed - Clinical trials for Advanced Solid Tumors

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Start date: December 6, 2017
Phase: Phase 1
Study type: Interventional

To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.

NCT ID: NCT04335253 Completed - Advanced Cancer Clinical Trials

First-In-Human Study of EOS884448 in Participants With Advanced Cancers.

Start date: February 18, 2020
Phase: Phase 1
Study type: Interventional

IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.

NCT ID: NCT04332419 Completed - Clinical trials for Hepatic Malignancies

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

Start date: March 3, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the results of positron emission tomography/computer tomography (PET/CT) to positron emission tomography/magnetic resonance imaging (PET/MRI) to help determine any added advantage of one over the other in relation to a tumor which might assist in further management plans.